Stockreport

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting [Yahoo! Finance]

Sonnet BioTherapeutics Holdings, Inc.  (SONN) 
PDF company developing innovative targeted biologic drugs, announced today that the SB221 study of SON-1010 (recombinant human Interleukin-12 linked to Sonnet's fully-human [Read more]